NAC Statement on Recombinant Factor VIIa

A literature search performed included publications from 2018-2023 confirmed that recombinant factor VIIa (rFVIIa) should be used for on-label indications only. A significant risk of thrombosis exists, which negates any benefit. Any use of (rFVIIa) outside of on-label indications should only be in the context of a clinical trial.

April 2012: On behalf of NAC, Dr. Yulia Lin et al. has revised the rFVIIa transfusion policy framework, which is available online as an open access publication: The evidence for the use of recombinant factor VIIa in massive bleeding: revision of the transfusion policy framework (nacblood.ca)

The National Advisory Committee on Blood and Blood Products would like to acknowledge and thank the Saskatchewan Health Authority Library and Librarian Mark Mueller for providing the literature search required to update this recommendation.

The evidence search report performed by the Saskatchewan Health Authority Library which informed this recommendation can be found on pages 3 to 20 here.